Primary Outcome Measures:
- Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation [ Time Frame: Up to 14 days after treatment discontinuation ]
Participants who recieved EZETROL® and experienced any adverse event related or unrelated to EZETROL®, within 14 days after treatment.
- Mean Percent Change From Baseline to Treatment in Lipid Parameters [ Time Frame: Baseline to 4 weeks ]
The mean percent change from baseline to treatment in lipid parameters (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides[TG]) in participants who received EZETROL over 4 weeks and then had available laboratory results in Lipid Parameters.
- Overall Efficacy Evaluation of EZETROL® [ Time Frame: Baseline to 4 weeks ]
Participants who received EZETROL over 4 weeks and then have been evaluated for overall efficacy assessment by investigator showing to be improved, unchanged or worsened.